An SND1-BRAF fusion protein has been identified in gastric, pancreatic and lung cancers that results in activation of downstream MAPK signaling and confers resistance to chemotherapeutic drugs[35–37] [Figure 1B]. Here, SND1 is linked to lung carcinoma.